Permanent 125I-seed prostate brachytherapy: Early prostate specific antigen value as a predictor of PSA bounce occurrence

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Mazeron, Renaud ^a,b   Bajard, Agathe ^a   Montbarbon, Xavier ^a   Gassa, Frédéric ^a   Malet, Claude ^a   Rocher, François ^a   Clippe, Sébastien ^a   Bringeon, Gabriel ^a   Desmettre, Olivier ^a   Pommier, Pascal ^a  

^a CENTRE LÉON BÉRARD   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

125 iodine permanent seeds; Biochemical relapse; Bounce; Brachytherapy; Prostate cancer; PSA

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN; RADIOACTIVE SEED; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; BRACHYTHERAPY; CANCER RELAPSE; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROSTATE CANCER; BLOOD; MIDDLE AGED; PROGNOSIS; PROSTATE TUMOR; RISK FACTOR; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84858729972     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-46     Document Type: Article

References (40)

1. Ash D, Flynn A, Battermann J, et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000, 57:315-321. 10.1016/S0167-8140(00)00306-6, 11104892.
2. Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999, 44:789-799. 10.1016/S0360-3016(99)00069-3, 10386635.
3. Critz FA. A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol 2002, 167:1310-1313. 10.1016/S0022-5347(05)65288-3, 11832720.
4. Critz FA, Levinson AK, Williams WH, et al. Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer. J Clin Oncol 1996, 14:2893-2900.
5. Stock RG, Klein TJ, Cesaretti JA, et al. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys 2009, 74:753-758. 10.1016/j.ijrobp.2008.08.049, 19084351.
6. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997, 37:1035-1041.
7. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-74. 10.1016/j.ijrobp.2006.04.029, 16798415.
8. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008, 8:268-278. 10.1038/nrc2351, 18337732.
9. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974. 10.1001/jama.280.11.969, 9749478.
10. Aaltomaa SH, Kataja VV, Lahtinen T, et al. Eight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy-morbidity and outcome results. Radiother Oncol 2009, 91:213-216. 10.1016/j.radonc.2008.12.009, 19167119.
11. Bostancic C, Merrick GS, Butler WM, et al. Isotope and patient age predict for PSA spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2007, 68:1431-1437. 10.1016/j.ijrobp.2007.01.066, 17544597.
12. Cavanagh W, Blasko JC, Grimm PD, et al. Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. Semin Urol Oncol 2000, 18:160-165.
13. Ciezki JP, Reddy CA, Garcia J, et al. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys 2006, 64:512-517. 10.1016/j.ijrobp.2005.07.960, 16213667.
14. Crook J, Gillan C, Yeung I, et al. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys 2007, 69:426-433. 10.1016/j.ijrobp.2007.03.031, 17869662.
15. Das P, Chen MH, Valentine K, et al. Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Int J Radiat Oncol Biol Phys 2002, 54:698-702. 10.1016/S0360-3016(02)03036-5, 12377320.
16. Hinnen KA, Monninkhof EM, Battermann JJ, et al. Prostate specific antigen bounce is related to overall survival in prostate brachytherapy. Int J Radiat Oncol Biol Phys 2011, 82:883-888.
17. Kanai K, Nakashima J, Sugawara A, et al. Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer. Int J Clin Oncol 2009, 14:502-506. 10.1007/s10147-009-0909-0, 19967485.
18. Kuban DA, Levy LB, Potters L, et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006, 65:1487-1493. 10.1016/j.ijrobp.2006.03.027, 16750326.
19. Makarewicz R, Roszkowski K, Lebioda A, et al. PSA bounces after brachytherapy HDR and external beam radiation therapy for prostate cancer. Rep Pract Oncol Radiother 2006, 11(5):217-222.
20. Merrick GS, Butler WM, Wallner KE, et al. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy. Brachytherapy 2003, 2:181-188. 10.1016/S1538-4721(03)00130-2, 15062141.
21. Mitchell DM, Swindell R, Elliott T, et al. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer. Radiother Oncol 2008, 88:102-107. 10.1016/j.radonc.2008.04.004, 18453022.
22. Patel C, Elshaikh MA, Angermeier K, et al. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant. Urology 2004, 63:110-113. 10.1016/j.urology.2003.08.025, 14751360.
23. Kirilova A, Damyanovich A, Crook J, et al. 3D MR-spectroscopic imaging assessment of metabolic activity in the prostate during the PSA "bounce" following 125iodine brachytherapy. Int J Radiat Oncol Biol Phys 2011, 79:371-378. 10.1016/j.ijrobp.2009.10.066, 20421147.
24. Satoh T, Ishiyama H, Matsumoto K, et al. Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis. BJU Int 2009, 103:1064-1068. 10.1111/j.1464-410X.2008.08234.x, 19040526.
25. Stock RG, Stone NN, Cesaretti JA. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int J Radiat Oncol Biol Phys 2003, 56:448-453. 10.1016/S0360-3016(02)04470-X, 12738319.
26. Caloglu M, Ciezki JP, Reddy CA, et al. PSA bounce and biochemical failure after brachytherapy for prostate cancer: a study of 820 patients with a minimum of 3 years of follow-up. Int J Radiat Oncol Biol Phys 2011, 80:735-741. 10.1016/j.ijrobp.2010.02.021, 20646846.
27. Critz FA, Williams WH, Levinson AK, et al. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age. J Urol 2003, 170:1864-1867. 10.1097/01.ju.0000091644.41330.2a, 14532794.
28. McGrath SD, Antonucci JV, Fitch DL, et al. PSA bounce after prostate brachytherapy with or without neoadjuvant androgen deprivation. Brachytherapy 2010, 9:137-144. 10.1016/j.brachy.2009.07.005, 19850537.
29. Morita M, Lederer JL, Fukagai T, et al. PSA bounce phenomenon after transperineal interstitial permanent prostate brachytherapy for localized prostate cancer. Nippon Hinyokika Gakkai Zasshi 2004, 95:609-615.
30. Pickles T. Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int J Radiat Oncol Biol Phys 2006, 64:1355-1359. 10.1016/j.ijrobp.2005.10.008, 16406391.
31. Thompson A, Keyes M, Pickles T, et al. Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces?. Int J Radiat Oncol Biol Phys 2010, 78:415-421. 10.1016/j.ijrobp.2009.07.1724, 20133083.
32. Toledano A, Chauveinc L, Flam T, et al. PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: a study of 295 patients with a minimum 3-year follow up. Brachytherapy 2006, 5:122-126. 10.1016/j.brachy.2006.02.003, 16644467.
33. Toledano A, Chauveinc L, Flam T, et al. PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure. Cancer Radiother 2007, 11:105-110. 10.1016/j.canrad.2006.10.005, 17158082.
34. Zwahlen DR, Smith R, Andrianopoulos N, et al. Prostate-Specific Antigen Bounce After Permanent Iodine-125 Prostate Brachytherapy-An Australian Analysis. Int J Radiat Oncol Biol Phys 2011, 79:179-187. 10.1016/j.ijrobp.2009.10.016, 20378267.
35. Merrick GS, Butler WM, Wallner KE, et al. Temporal effect of neoadjuvant androgen deprivation therapy on PSA kinetics following permanent prostate brachytherapy with or without supplemental external beam radiation. Brachytherapy 2004, 3:141-146. 10.1016/j.brachy.2004.07.002, 15533806.
36. Horwitz EM, Levy LB, Thames HD, et al. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer 2006, 107:1496-1502. 10.1002/cncr.22183, 16944536.
37. Feigenberg SJ, Hanlon AL, Horwitz EM, et al. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer. Am J Clin Oncol 2006, 29:458-462. 10.1097/01.coc.0000225410.37469.58, 17023779.
38. Hanlon AL, Pinover WH, Horwitz EM, et al. Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys 2001, 50:845-849. 10.1016/S0360-3016(01)01557-7, 11429210.
39. Reed D, Wallner K, Merrick G, et al. Clinical correlates to PSA spikes and positive repeat biopsies after prostate brachytherapy. Urology 2003, 62:683-688. 10.1016/S0090-4295(03)00505-3, 14550443.
40. Ghilezan M, Park S, Ye H, et al. A modified Phoenix biochemical failure (BF) definition to account PSA bounce phenomenon for prostate cancer patients treated with brachytherapy (BT). Int J Radiat Oncol Biol Phys 2009, 75:S311.